We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,800
Open access books available

116,000
International authors and editors

120M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Pharmacological Therapy for Recurrent Obscure Gastrointestinal Bleeding

Javier Molina-Infante, Gema Vinagre-Rodriguez and Miguel Fernandez-Bermejo
Department of Gastroenterology,
Hospital San Pedro de Alcantara, Caceres, Spain

1. Introduction

Obscure gastrointestinal bleeding (OGIB) is defined as occult or overt bleeding of unknown origin that persists or recurs despite negative primary radiological and endoscopic studies. It can be classified into two different clinical forms: obscure-overt OGIB, defined as visible passage of blood (i.e., melena or hematochezia) and obscure-occult OGIB, manifested by iron-deficiency anemia or positive fecal occult blood test without other evidence of bleeding. Since the source of bleeding is not readily identifiable by upper GI endoscopy and colonoscopy, OGIB is therefore, by definition, recurrent. Approximately, 5% of GI bleeding occurs between the ligament of Treitz and the ileocecal valve. Angiodysplasias of the small bowel account for 30% to 40% of OGIB and are the most common source of bleeding in patients over 60 years.1,2 They can be found as a primary disease or a gastrointestinal manifestation of systemic diseases such as hereditary haemorrhagic telangiectasia (HHT), von Willebrand (vW) disease, cardiac valvular disease, radiation enteritis, end-stage renal disease, portal hypertension, connective tissue diseases or vasculitis. Other causes include non-steroidal anti-inflammatory drugs enteropathy, inflammatory bowel disease, small bowel tumors (i.e., leiomyomas, carcinoid, lymphomas, adenocarcinomas), Meckel’s diverticulum or Dieulafoy’s lesion.

Over the last decade, the diagnostic yield and therapeutic capabilities of small bowel endoscopy have dramatically changed with the development of video capsule endoscopy and deep enteroscopy systems (single balloon, double balloon or spiral). Nonetheless, the diagnostic yield is 75% at best combining both techniques, so a quarter of patients lack a diagnosis of the source of bleeding despite exhaustive evaluation and may be at high risk of rebleeding.1 Additionally, a variable percentage of patients with a diagnosis may not respond to endoscopic therapy or may not be tributary to aggressive endoscopic or surgical management due to severe comorbidities or diffuse distribution of lesions throughout the GI tract. In this particular subset of patients, medical therapy is commonly required to stop, or at least, ameliorate bleeding, which usually leads to high transfusional requirements, exacerbations of medical conditions and subsequent hospital admissions. Indications for medical therapy in OGIB, as approved in the latest American Gastroenterology Association technical review, are listed in Table 1.2
1. Patients who are not candidates or do not respond to endoscopic, surgical or interventional radiological therapy.

2. Diffuse vascular lesions in the small bowel or extended to upper or lower segments.

3. Relative unaccessible location of lesions for endoscopy.

4. Unknown source of bleeding.

Table 1. Indications for pharmacological therapy in OGIB

The aim of this chapter is to give an overview of current scientific evidence supporting the use of pharmacological therapy in these, often difficult to treat, OGIB patients. The standard diagnostic and therapeutic approach involving endoscopic and radiological techniques, the management of concomitant antiplatelet and anticoagulant drugs and the supportive care of anemia in OGIB patients, are described elsewhere. Up to date, data regarding pharmacological agents for OGIB are scarce and exclusively based on case reports and small uncontrolled studies. The available evidence suggests a potential role for pharmacological therapy as an adjunctive measure in patients with either multiple comorbidities or in whom lesions are inaccessible or refractory to endoscopic therapy. However, their clinical utility remains to be proven in randomized controlled trials. Similarly, the appropriate dose and schedule required for long-term therapy are also unknown. The different pharmacological agents used for OGIB reported in the literature are listed in Table 2.

Hormonal therapy

Somatostatin analogues
Octreotide
Long acting release (LAR) octreotide
Lanreotide

Antiangiogenic drugs
Thalidomide
Lenalidomide
Bevacizumab

Miscellaneous
Antifibrinolytics (aminocaproic acid, tranexamic acid)
Danazol
Desmopressin
Recombinant activated factor VII
Tamoxifen
Non selective beta-blockers

Table 2. Pharmacological agents used in OGIB
Depending on the type of bleeding
- Life-threatening: vasoactive medication, rFVIIa

Depending on the source of bleeding
- Angiodysplasias: long-acting somatostatin analogues, antiangiogenic drugs (thalidomide, lenalidomide)
- Hereditary hemorrhagic telangiectasia: antifibrinolytics, tamoxifen, antiangiogenic drugs (thalidomide, bevacizumab)
- Portal hypertension: beta-blockers
- von Willebrand disease: desmopressin, vW factor, antifibrinolytics

Table 3. Suggested therapeutic algorithm for pharmacological therapy in OGIB

2. Hormonal therapy

Estrogen-progesterone combination was proposed for OGIB because of preliminary reports of improvement of epistaxis in patients with HHT during pregnancy and further relapse in the puerperium. Its effect, which is not immediate, seems to be estrogen dose-dependent and acts by enhancing microvascular circulation, coagulation, and vascular endothelial integrity. The most common combination schedule has been ethynil estradiol 0.01-0.05 mg and norethisterone 1-3 mg. This therapy should be used over six-month periods with pauses to reduce the incidence of adverse effects, mostly due to the estrogen component (vascular thrombosis, gynecomastia and loss of libido in men, breast tenderness and vaginal bleeding in women). However, the two largest placebo-controlled studies addressing the impact of hormonal therapy on GI bleeding from angiodysplasias failed to demonstrate any significant benefit. In the first study, patients with out-of-reach bleeding small-bowel angiodysplasias were treated using high-dose estrogens, estrogen-progesterone or placebo, but no statistical improvement of transfusion requirements was observed amongst the groups. Additionally, in the second study, the authors failed to identify any significant effect of hormonal therapy compared to placebo in 72 non-cirrhotic patients bleeding from documented angiodysplasia. This latter study, however, has setbacks such as the use of low doses of ethynil estradiol and the exclusion of patients with vascular ectasia associated to cirrhosis and HHT. Overall, the effectiveness of hormonal therapy remains unclear and both negative controlled trial results and serious and frequent side effects strongly limit its use in OGIB. Recent reports on the effectiveness of other agents with an improved safety profile displace hormonal therapy as first-line therapeutic option for OGIB.

3. Somatostatin analogues

In 1993, octreotide was first reported for the treatment of bleeding small bowel angiodysplasias, in a small series of three patients successfully treated for 10 to 40 months. The rationale for the use of somatostatin analogues is based on its effects on splanchnic circulation, as they induce a marked reduction of portal and mesenteric blood flow mediated through inhibition of vasodilator peptides. Additionally, experimental studies have shown that octreotide has antiangiogenic effects, by downregulation of vascular...
endothelial growth factor (VEGF). In fact, a study reported endoscopic resolution of angiodysplastic lesions after treatment with octreotide, albeit the effect was not quantified. Interestingly, a more recent study showed that a 3-month-treatment of long-acting release (LAR) octreotide 20 mg once a month in cirrhotic patients decreased significantly both the hepatic venous pressure gradient and VEGF in hepatic venous blood. Other potential mechanisms of action of somatostatin analogues in OGIB, although more controversial, are by increasing vascular resistance and improving platelet aggregation.

Octreotide is, by far, the most studied somatostatin analogue in OGIB. However, recent studies are focusing on long-acting intramuscular (LAR octreotide) or subcutaneous (lanreotide) formulations, which have the great advantage of a once monthly administration. A recent meta-analysis, which included three prospective studies, aimed at evaluating the effectiveness of conventional and depot somatostatin analogues for bleeding vascular malformations, showed an average clinical response rate of 76%. Despite the small sample size of the studies included and the heterogeneity in the dose and molecular forms of the medication, these results are encouraging and a trial of somatostatin analogues is warranted, especially in patients in whom endoscopic therapy has failed, with unaccessible lesions or unknown source of bleeding. Its good safety profile, when compared with other pharmacological agents such as hormonal therapy or thalidomide, is another meaningful advantage. Nonetheless, randomized controlled trials are needed to confirm this data.

3.1 Octreotide

Octreotide can be administered intravenously (50 µg per hour) or subcutaneously (50-100 µg b.i.d or t.i.d). Its main disadvantage for long-term therapy is the need of parenteral administration several times a day, owing to its short half-life (90-120 minutes). Octreotide has been reported successful in stopping GI bleeding from angiodysplasia in multiple case reports and small series, both in acute and chronic bleeding. To date, the most solid evidence is obtained in two prospective cohort studies, the latter comparing the results to historical controls. The former included 17 patients, (of whom 6 were cirrhotic), with chronic bleeding from angiodysplasias. 7 patients had isolated angiodysplasias, whereas other 7 had diffuse lesions in upper and lower segments of the GI tract and 3 watermelon stomach. Octreotide was given subcutaneously (100 µg t.i.d) for 6 months. More than half of the patients (10/17) achieved complete remission without further iron or transfusion requirements, whereas a transient improvement was observed in another 4 patients. Of note, octreotide lead subjectively to disappearance or reduction of the number, size and colour of the vascular malformations on follow-up endoscopy. The second study included 32 patients with acute or chronic bleeding due to GI angiodysplasias, which were treated with octreotide 50 µg b.i.d for a 1-2 yr period. Cirrhotic patients were excluded. Treatment failure (rebleeding or iron deficiency anemia during follow-up) was significantly higher in the controls cohort (48%) in comparison with the octreotide cohort (23%). A significant decrease in iron requirements, but not in hemoglobin or transfusion requirements, was also observed in the octreotide arm. Adverse effects in both studies were uncommon and mild, including diarrhea, constipation, hyperglycemia or gallbladder stones.

3.2 Long-acting release (LAR) octreotide

Several case reports and small series have recently revealed the efficacy of a depot formulation of octreotide (LAR octreotide) for severe OGIB, either of unknown origin or
related to diffuse small bowel angiodysplasias.\textsuperscript{13-18} LAR octreotide is administered intramuscularly monthly, which makes it an attractive and comfortable therapy on an outpatient basis.

Two small prospective uncontrolled series have been published using LAR octreotide. In the first study, 13 patients with chronic GI bleeding due to angiodysplasias were treated with octreotide LAR 10 mg per month and followed for at least 1 year.\textsuperscript{19} Nine out of the thirteen patients (69\%) did not require further blood or iron supplementation, and partial improvement was also observed in another patient. The second study addressed the response to octreotide LAR 20 mg per month in a cohort of 11 elderly patients with multiple comorbidities and severe OGIB, mostly related to small-bowel diffuse angiodysplasia (72\%).\textsuperscript{20} Median follow-up was 15 months (5-48). Only 2 out of 11 patients (18\%) remained free of transfusions. However, a significant decrease in the need of red cell packets (14 (9-49) vs 4 (0-9), p 0.002) and in hospital stay due to GI bleeding (27 days (10-99) vs 7 days (0-23), p<0.001) during the first year of treatment was observed. These less promising results were perhaps due to a higher proportion of patients on anticoagulation or antiplatelet therapy, which was not withdrawn at study inclusion. Furthermore, the patients included in this study had more severe GI bleeding as shown by higher transfusional requirements. The main disadvantage of this drug formulation is its high cost, ranging from 785 euros (10mg) to 1300 euros (30 mg) monthly. However, it may be cost-effective in very specific difficult to treat patients, only tributary to conservative management, with higher transfusional requirements and repeat admissions.

3.3 Lanreotide

The main advantage of lanreotide over LAR octreotide is its subcutaneous administration, avoiding painful intramuscular injections and their inherent risk for complication in anticoagulated or cirrhotic patients. Up to date, there is only a case report on the successful use of lanreotide in a patient with severe OGIB due to universal portal hypertension stigmata in stomach, small bowel and colon.\textsuperscript{21} After a successful response to octreotide at a dose of 100 µg twice a day, the patient was given lanreotide, administered at dose of 60 mg, subcutaneously, on a monthly basis. This drug achieved complete remission of bleeding during 15 months of follow-up.

4. Antiangiogenic drugs

4.1 Thalidomide

Thalidomide is a drug with powerful immunomodulatory, anti-inflammatory and antiangiogenic effects, banned in the 1960s because of its teragenocity. However, it has been recently reintroduced for the treatment of leprosy, multiple myeloma and a variety of tumors. Over the last decade, thalidomide has gained interest as a therapeutic tool for OGIB. The rationale for its use in bleeding GI angiodysplasias is based on the inhibition of VEGF-dependent angiogenesis. It is administered orally at a variable dose of 100-300 mg per day, usually during a 3-month course due to adverse effects.

Thalidomide has been reported to be effective in controlling refractory severe bleeding from small bowel angiodysplasia, bleeding portal hypertensive gastropathy and enteropathy, radiation-induced proctitis and Crohn’s disease.\textsuperscript{22-29} Thalidomide, at a dose of 100 mg per day for three months, controlled OGIB in a case series of 3 patients with chronic bleeding from small-bowel angiodysplasia evidenced by capsule endoscopy.\textsuperscript{30}
endoscopy after therapy revealed a substantial reduction in lesion number, size and colour intensity. Of note, the response was sustained for a median of 34 months despite discontinuation of the drug. Due to its antiangiogenic property, thalidomide may not only lead to cessation of bleeding but also to prevention of further angiodysplasia formation. More recently, two small prospective series, involving 3 and 7 patients, respectively, have confirmed the utility of thalidomide for bleeding small-bowel angiodysplasia. However, a high rate of discontinuation was observed in these series (1/3 and 4/7, respectively), owing to intolerable side effects (fatigue, peripheral neuropathy, dizziness, urticarial rash). The main drawback of thalidomide is its frequent side effects, although these are mostly minor (fatigue, somnolence, constipation, dizziness, peripheral neuropathy). Nonetheless, fatal complications such as acute liver failure have been reported. In addition, the risk of thromboembolic events associated with thalidomide should be considered in OGIB patients. Overall, thalidomide is an effective drug for refractory bleeding GI angiodysplasia. Taking into account its numerous side effects, it seems cautious to save thalidomide for OGIB refractory to both endoscopic therapy and a trial of somatostatin analogues, albeit a head-to-head comparison is required to validate this algorithm.

4.2 Lenalidomide
Lenalidomide is an antiangiogenic drug commonly used for multiple myeloma. It has two major advantages over thalidomide: a more powerful antiangiogenic effect and a lower toxicity profile. Its use in the context of life-threatening bleeding due to gastrointestinal angiodysplasia in a patient suffering from HHT, in whom thalidomide was effective but had to be stopped because of severe neuropathy has been recently reported. Lenalidomide successfully controlled bleeding and the patient remained free of either gastrointestinal bleeding or drug symptoms. However, although lenalidomide is more effective and better tolerated than thalidomide, further studies are warranted to evaluate its role in refractory OGIB. On the other hand, lenalidomide is 10 times more expensive than thalidomide and dosing should be carefully titrated owing to severe bone marrow suppression, much higher than that described for thalidomide.

4.3 Bevacizumab
Recently, a growing number of reports on the use of VEGF antagonist bevacizumab in HHT have lead to outstanding improvement in GI bleeding episodes, reductions in cardiac output and liver size, even obviating the need for liver transplantation in a single patient. This benefit has been also proven for recurrent epistaxis, administering bevacizumab intravenously, injected locally or sprayed topically to the nasal mucosa.

5. Miscellaneous drugs
5.1 Antifibrinolytics
Aminocaproic acid is a powerful inhibitor of the fibrinolytic system that blocks conversion of plasminogen to plasmin when used at low doses. There is only one isolated report in which it was effective in the management of epistaxis from arteriovenous malformations in two patients with HHT at a dose of 1.5 g twice a day, although it was not clear whether concomitant gastrointestinal bleeding was present. Tranexamic acid is a synthetic lysine analog that inhibits the conversion of plasmin to fibrinogen, with less antifibrinolytic power than aminocaproic acid. Tranexamic acid has
been proven useful for chronic bleeding from angiodysplasias in patients with end-stage renal failure and bleeding gastric antral vascular ectasia in cirrhosis.\textsuperscript{40-42} A systematic review on the use of tranexamic acid for upper GI bleeding was recently published.\textsuperscript{43} Although it seemed to reduce overall mortality, there were no significant differences regarding bleeding, surgery or transfusion requirements. Of note, tranexamic acid did not increase thromboembolic risk. Therefore, the current evidence does not support routine use of tranexamic acid in clinical practice. The main risk derived from the use of antifibrinolytics is thrombosis, so thrombophilia should be ruled out before prescribing them. Adverse events associated to ACA and tranexamic acid may be frequent, and the use of these drugs is not supported by randomized controlled trials, which makes antifibrinolytics a last option for OGIH.

5.2 Danazol
Danazol is an anti-gonadotropin drug with weak androgenic activity that blocks pituitary secretion of FSH and LH, leading to ectopic and normal endometrial tissue atrophy. It has been widely used for endometriosis and uterine bleeding disorders. Anecdotal reports suggest a partial improvement with danazol in patients with gastrointestinal bleeding and HHT,\textsuperscript{44-46} although cosmetic stigmata (acne, hair loss, mild hirsutism) and uncommon but severe adverse effects (intracranial hypertension, peliosis hepatitis, thrombosis, seizures) leave danazol to a secondary role in OGIH, when other therapies have failed.

5.3 Desmopressin
Desmopressin is a synthetic analog of the antidiuretic hormone vasopressin that lacks vasopressor activity. It increases vWF factor and factor VIII levels, and also enhances hemostasis in patients with defective platelet function. It is indicated as a hemostatic therapy for patients with hemophilia A and von Willebrand’s disease, and can be administered intravenously, subcutaneously, or by intranasal spray. An isolated report showed a benefit of intravenous desmopressin for life-threatening gastrointestinal bleeding in a patient with HHT and vW factor deficiency, allowing elective colectomy and bleeding resolution\textsuperscript{47}.

5.4 Recombinant activated factor Vila
Recombinant activated human factor VII (rFVIIa) is a drug that strongly promotes hemostasis, and is currently indicated for hemophiliac A and B patients with antibody inhibitors to coagulation factors VIII or IX, congenital deficiency of factor VII, and Glanzmann’s thrombasthenia. This drug has been used anecdotally for stopping hemorrhage, with or without hematological disorders, in massive or uncontrollable bleeding at multiple GI and non GI locations. Its short half-life of 2 hours requires frequent boluses or continuous infusion to achieve hemostasis, and it can induce definite control of bleeding or be a bridge until a causal therapy can be provided. It has been mainly used in cirrhotic patients with acquired coagulation factor deficiencies, especially in variceal and non-variceal upper GI hemorrhage related to cirrhosis or acute liver failure.\textsuperscript{48,49} Albeit preliminary results showed that it might have a beneficial effect for advanced cirrhotic patients with variceal bleeding, a randomized placebo controlled trial failed to demonstrate a significant benefit of rFVIIa for controlling variceal bleeding or preventing rebleeding in these patients.\textsuperscript{50} Thus, the use of rFVIIa should be carefully individualized in cirrhotic patients and it is not recommended in the routine clinical practice.
This drug has been proven useful in other settings as well. In a series of 11 unselected patients with upper GI haemorrhage, half of them related to liver disease, rFVIIa stopped the bleeding in 7 patients and markedly reduced it in other 2 patients. Other successful indications relating severe GI bleeding have been refractory bleeding after endoscopic sphincterotomy in patients with preexisting coagulopathy, severe recurrent GI bleeding due to multiple GI angiodysplasias in a patient with vWF disease, massive colonic bleeding or exsanguinating bleeding due to Mallory-Weiss tear. Of note, no thromboembolic events were reported in the aforementioned trials or series. However, secondary myocardial and cerebrovascular infarctions have been described while using factor VIIa. As such, it is important to stress once more that the use of this drug should always be carefully individualized.

5.5 Tamoxifen
In a recent randomized, double-blind placebo controlled trial, the efficacy of antiestrogen therapy (Tamoxifen) was evaluated in patients with epistaxis due to HHT. There was a significant reduction in the frequency of epistaxis in the tamoxifen-treated group, frequently associated to a rise in haemoglobin or a reduction in transfusion requirements. As previously mentioned in the case of bevacizumab, a potential therapeutic role for GI bleeding in HHT patients warrants further research.

5.6 Non-selective beta-blockers
These drugs aim to control hemorrhage by reducing gastrointestinal blood flow due to splanchnic vasoconstriction and reduction of cardiac output in cirrhotic patients with portal hypertension. Its proven benefit for secondary prophylaxis of bleeding portal hypertensive gastropathy in two randomized controlled trials led to the consensus recommendation that beta-blockers should be used for chronic bleeding once the acute episode of bleeding is

6. References


Endoscopy has had a major impact in the development of modern gastroenterology. By using different data it provided a better understanding of pathogenic mechanisms, described new entities and changed diagnostic and therapeutic strategies. Meanwhile, taking advantage of many technical advances, endoscopy has had a developed spectacularly. Video-endoscopes, magnification, confocal and narrow-band imaging endoscopes, endoscopic ultrasounds and enteroscopes emerged. Moreover, endoscopy has surpassed its function as an examination tool and it became a rapid and efficient therapeutic tool of low invasiveness. InTech Open Access Publisher selected several known names from all continents and countries with different levels of development. Multiple specific points of view, with respect to different origins of the authors were presented together with various topics regarding diagnostic or therapeutic endoscopy. This book represents a valuable tool for formation and continuous medical education in endoscopy considering the performances or technical possibilities in different parts of the world.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
